CBLL · CeriBell, Inc.

Current Thesis

Ceribell’s reimbursement-backed delirium expansion needs a Q4 2026 commercial launch and a weekly close above the market’s $24.89 reference high to confirm the next leg; a weekly close below $21.50 invalidates the price thesis. The Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case on 2026-08-03, effective 2026-10-01. That establishes hospital reimbursement eligibility; it does not establish Ceribell orders. Company reimbursement announcement.

The August 30 assessment of analyst silence is now stale: Investing.com reported on 2026-09-11 that BTIG reiterated its $30 price target and discussed a physician survey. The inference remains that the narrative is maturing — September coverage revisits the August reimbursement story at an unchanged BTIG target, while the 2026-09-11 adjusted close of $23.63 remains below the supplied $24.89 reference high. This evidence establishes renewed coverage, without establishing broader participation. September 11 BTIG report.

Bullish and bearish views on CeriBell, Inc.

The model's bull view on CeriBell, Inc. (CBLL), in brief: Core revenue supports the expansion. Ceribell reported Q2 2026 revenue of $28.1 million, up 33% year over year, and 712 active accounts on 2026-08-10. Management raised full-year revenue guidance to $114–117 million; a subsequent reduction below that range would weaken this… The bear view: Spending outpaced revenue growth. The 2026-08-10 results reported Q2 operating expenses of $45.9 million, up 37% year over year, and a net loss of $19.3 million. Another quarter with expense growth exceeding revenue growth would confirm that operating leverage remains absent. Q2… Both cases follow in full.

Bull Case

• Core revenue supports the expansion. Ceribell reported Q2 2026 revenue of $28.1 million, up 33% year over year, and 712 active accounts on 2026-08-10. Management raised full-year revenue guidance to $114–117 million; a subsequent reduction below that range would weaken this operating support. Q2 results.
• Reimbursement has an effective date. The 2026-08-03 announcement specifies 2026-10-01 for the delirium NTAP. The inference is that payment eligibility supports commercialization; failure to launch within management’s Q4 2026 window would break the timing case. NTAP announcement.
• Existing users expressed interest. Investing.com’s 2026-09-11 account of BTIG’s survey says 79% of 24 surveyed US Ceribell users planned to adopt the delirium monitor. This measures stated intentions among existing users; the sample is too small to support a claim about broad hospital adoption. BTIG survey coverage.

Bear Case

• Spending outpaced revenue growth. The 2026-08-10 results reported Q2 operating expenses of $45.9 million, up 37% year over year, and a net loss of $19.3 million. Another quarter with expense growth exceeding revenue growth would confirm that operating leverage remains absent. Q2 results.
• Reported margin included temporary help. Management attributed part of Q2 2026’s 92% gross margin to one-time tariff refunds in the 2026-08-10 reporting. A subsequent margin below that quarter’s level would confirm that the reported peak was not sustained. Q2 results.
• Hospital payment differs from company revenue. Ceribell’s 2026-05-11 quarterly filing says the company invoices healthcare providers rather than third-party payers and warns that reimbursement constraints can impede adoption. Payment eligibility beginning 2026-10-01 without a Q4 commercial launch would leave the conversion thesis unfulfilled. Q1 Form 10-Q.

Setup & Price Structure

The supplied adjusted market series records a $23.63 close on 2026-09-11, 5.1% below its $24.89 52-week high, with a three-month price increase of 27.9%. Its 14-period relative strength index (RSI) reads 43.5. Those measurements show a positive medium-term price change alongside weaker recent momentum; they do not establish a completed base.

The $21.50 threshold is the research invalidation level published on 2026-08-30, retained for continuity. The available price context does not independently establish it as a moving average or a repeatedly tested support shelf. A weekly close above the supplied $24.89 high would meet the price-confirmation condition; a weekly close below $21.50 would end this continuation thesis.

The positioning evidence remains limited. The August Form 4 record includes executive open-market sales on 2026-08-19 and tax-withholding dispositions on 2026-08-21; those transaction types cannot be treated as equivalent discretionary signals. BTIG’s 2026-09-11 reiteration establishes analyst attention, while current short-interest, retail-flow and moving-average measurements are missing. Neither crowding nor an absence of crowding is established.

Catalyst Calendar (next 30 days)

• 2026-10-01 — Delirium reimbursement becomes effective. Ceribell’s 2026-08-03 announcement specifies the start of the NTAP of up to $2,171 per eligible Medicare inpatient case. This resolves the payment timetable, not the commercial launch or order volume. Company announcement.

As checked on 2026-09-13, the company’s events page provides no confirmed upcoming earnings date. Management’s Q4 2026 launch window remains the later commercial test, but no day-level launch date is established in the available evidence. Company events, September 11 launch coverage.

What Would Change Our Mind

Failure of the August continuation structure would end the market thesis: a weekly close below $21.50 breaches the threshold published on 2026-08-30. Commercially, an announced postponement beyond Q4 2026 or a reduction below the $114–117 million full-year revenue guidance issued on 2026-08-10 would break a supporting premise.

The positive case is defined as a confirmed Q4 2026 commercial launch accompanied by a weekly close above the supplied $24.89 reference high before the invalidation close occurs. The 2026-09-11 BTIG survey supports interest but cannot substitute for the launch; the 2026-10-01 payment date alone is insufficient.

Correlation Notes

This remains a single-company medtech setup. The dated drivers are Ceribell’s 2026-08-03 reimbursement announcement and 2026-08-10 operating results; no peer-return series or measured sector correlation accompanies the 2026-09-11 price evidence. A claim that a healthcare group move confirms this thesis is therefore unsupported.

Ceribell’s 2026-08-03 announcement describes seizure and delirium monitoring on the same platform. That establishes shared product exposure, but it provides no measured stock-price correlation with other diagnostic companies. Platform description.